You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
10x will develop a third genomics platform, possibly combining Cartana's more sensitive chemistry with ReadCoor's instrument.
Sengenics has largely focused its full-length folded protein arrays technology on research into cancer and autoimmune and infectious disease including COVID-19.
The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.
Called the Integrated Proteomics Pipeline, the platform offers search engine capabilities that will enable better use of collision cross section data.
The deal expands Illumina's cloud-based data analysis portfolio and gives its customers access to tools to boost assay and operational efficiency.
UK-based Abcam has acquired Oregon-based life science research tool provider Marker Gene Technologies, the latest in a string of asset purchases.
The company expects that Blueprint's informatics capabilities in particular will improve variant interpretation and reporting across all its genetic test offerings.
Abcam said that acquisition will help it build out a discovery engine for developing novel edited cell lines and support its knockout validation initiative.
Psomagen is buying bankrupt microbiome testing firm uBiome's assets, Stat News reports.
The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.
Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner.
Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.
A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.
In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.